Gossamer Bio, Inc.
GOSS•NASDAQ•Healthcare•Biotechnology

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOFaheem Hasnain
Founded2015
IPO DateFebruary 8, 2019
Employees145
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.gossamerbio.com
Phone858 684 1300
Address
3115 Merryfield Row, Suite 120 San Diego, California 92121 United States

Corporate Identifiers

CIK0001728117
CUSIP38341P102
ISINUS38341P1021
EIN47-5461709
SIC2834

Leadership Team & Key Executives

Faheem Hasnain
Co-Founder, Chief Executive Officer, President and Chairman
Bryan Giraudo
Chief Operating Officer and Chief Financial Officer
Dr. Richard Aranda M.D.
Chief Medical Officer
Christian Waage J.D.
Executive Vice President of Technical Operations and Administration
Jeff Boerneke
General Counsel and Secretary
Jeanine Anthony
Senior Vice President of Marketing
Deanna Weber
Executive Vice President of Human Resources
Dr. Robert F. Roscigno Ph.D.
Senior Vice President of Clinical Development of Pulmonary Vascular Disease
Caryn L. Peterson
Executive Vice President of Regulatory Affairs
Matt Cravets
Senior Vice President of Biometrics